InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by Alexandre Merieux, Président exécutif de bioMérieux. Insider active across 1 companies, notably BIOMERIEUX. Aggregated, 8 filings have been recorded. Total volume traded: €81m. The latest transaction was disclosed on 25 March 2025 — Transfert à titre gratuit d'actions. Regulator: AMF. All data is accessible without signup.
Declarations8 total
€2bn2,152,868 shares@ €1,095.164823.2% of flow
Actions de Compagnie Mérieux AllianceHors plateforme de négociation
2025DD1027996·
€2bn2,152,868 shares@ €1,095.164823.2% of flow
Actions de CMAHors plateforme de négociation
2025DD1027997·
€706m778,699 shares@ €906.837533.3% of flow
Actions de Compagnie Mérieux Alliance et de AME HoldingHors plateforme de négociation
2025DD1013673·
€706m778,699 shares@ €906.837533.3% of flow
Actions de Compagnie Mérieux Alliance et de MHC HoldingHors plateforme de négociation
2025DD1013681·
€706m778,699 shares@ €906.837533.3% of flow
Actions de Compagnie Mérieux Alliance et de APC HoldingHors plateforme de négociation
2025DD1013686·
€2bn2,336,097 shares@ €906.837520.8% of flow
Actions de Compagnie Mérieux Alliance, AME Holding, MHC Holding et APCHors plateforme de négociation
2024DD1012649·
€81m58,148 shares@ €1,393.040.62% mcap100.0% of flow
Actions de Compagnie Mérieux AllianceHors plateforme de négociation
2024DD1006251·
Ideal exit: 1 Jul 2025 (T+270)
€1bn870,333 shares@ €1,393.0411.9% of flow
Actions de Compagnie Mérieux AllianceHors plateforme de négociation
2024DD1006257·
8 of 8 declarations
About Alexandre Merieux
Alexandre Mérieux is currently the Executive Chairman of bioMérieux, following a sequence of leadership roles that included Chief Executive Officer and Chairman and CEO. He joined the company’s Board of Directors in 2004, was appointed Deputy Chief Executive Officer in 2008, became Chief Executive Officer in 2014, and then Chairman and CEO in 2017 before the company separated the Chairman and CEO roles in 2023. His career reflects a gradual rise through the group and a strong continuity within the Mérieux family’s long-term stewardship of the business. He holds a degree in biology from Lyon I University and is a graduate of HEC Montréal. Before joining bioMérieux, he spent five years at Silliker Group Corporation from 1999 to 2004, working in marketing roles in the United States and Europe and later in a marketing and business unit leadership position in France. He joined bioMérieux in 2005 as Executive Vice President, Industrial Microbiology, and later served as Corporate Vice President of the Microbiology and Industrial Operations unit from 2011 to 2014. Beyond bioMérieux, he has held senior responsibilities within the Institut Mérieux ecosystem, including Vice-President of Institut Mérieux since 2008, Chairman of Mérieux Développement since 2009, and Chairman of the Board of Mérieux NutriSciences since 2013. This background has given him recognized expertise in industrial microbiology, in vitro diagnostics, international market development, and family-controlled group governance. As bioMérieux’s top executive, he has overseen the company’s strategic continuity and governance evolution, including the 2023 move to a structure with a separate Chief Executive Officer. His leadership combines technical credibility, international operational experience, and strong familiarity with listed-company governance, positioning him as a central figure in the group’s long-term development.
